Key Visual




LOTTE BIOLOGICS was established in 2022, and is headquartered in Seoul, South Korea.
LOTTE BIOLOGICS will be entering the biologics CDMO business after acquiring Bristol Myers Squibb’s Syracuse biologics drug substance manufacturing site, which is expected to be completed in 2022.
The newly established organization aims to become a Global Top 10 CDMO company in the biopharmaceutical industry.

With initial operations in 1948 in Japan, LOTTE has grown to become the fifth-largest conglomerate corporation in South Korea.
LOTTE has various business units, including petro/fine chemicals, food, retail, hotels, electronics, construction, and IT.
LOTTE has 30+ global locations across the US, Europe, and Asia.

LOTTE BIOLOGICS is a biological CDMO (Contract Development Manufacturing Organization) company that provides a high level of manufacturing services from clinical to commercial products.
To be the most trusted partner in the industry with high standards of quality and innovative technologies that reliably deliver benefits for patients worldwide.
To Deliver Therapies that Enable a Healthier World.
Our Credo
Our highest priority is to advance the quality of health of our end customers, our patients.
By improving the health of the users of our products, we improve lives on a global scale and contribute to making a positive impact on the world.

To achieve these goals, our leadership team will be held to the highest standard when collaborating with like-minded partners who share our core values.
We will embrace, serve, and stay loyal to our partners while employing the latest standards and technologies in manufacturing, such as sustainable clean energy, automation, AI, and quality systems.

We will be bold, decisive, and agile when a need for change or innovation is recognized.

We believe in improving the lives of our diverse workforce and their families by providing a safe work environment where each individual’s rights are respected.
We will provide careers that are secure and fulfilling. Our employees, in return, will be committed to ensuring quality output by taking personal responsibility for their roles in the quality process.

To serve the interests of the partners and end customers, we will adhere to strict security and confidentiality standards for our and their data.
We will meet the highest standards for customer satisfaction by assuring the delivery of quality products.

We will stay focused on building long-term value of our company by exceeding performance for our investors and stockholders.

Core Values

Inspired by Science

Inspired by Science

Embracing Diversity

Embracing Diversity

Fostering Talent

Fostering Talent

Connecting Lives

Connecting Lives

Our Leadership Team

Richard W.Lee
Richard Lee is the Chief Executive Officer of LOTTE BIOLOGICS and serves on its Board of Directors. With over 20 years of global biologics and pharmaceutical industry experience, Mr. Lee is dedicated to building a world-class Contract Development and Manufacturing Organization for Biopharmaceuticals for the LOTTE Group.

Prior to joining LOTTE in 2021, Mr. Lee was a founding member of Samsung Biologics and led its Drug Product Business Unit providing strategic direction across finance, business development, HR, technical operations, regulatory management, expansion engineering, and supply chain management. With industry experience across Samsung Biologics, Bristol-Myers Squibb, and Chiron, Mr. Lee has developed a strong, quality-driven approach to delivering biopharmaceuticals.

Mr. Lee's many accomplishments include successful company launches as well as multiple product and facility approvals, which led to continued revenue growth for his organizations. A believer in the power of technology to accelerate progress in the manufacturing of biopharmaceuticals and recognizing the large unmet need for contract manufacturing capacity for biologics, Mr. Lee is leading LOTTE BIOLOGICS to meet this need in the most rapid and reliable way possible.

Mr. Lee holds a bachelor's degree from the University of California, Berkeley.
Hun Ki Lee
Hun Ki Lee is the Executive Chairman of LOTTE BIOLOGICS and has the dual role of Chairman and Chief Strategic Officer (CSO) of LOTTE Corporation.

As the CSO of Korea’s fifth-largest corporation, Mr. Lee leads LOTTE’s business strategy, mergers & acquisitions, ESG (Environmental, Social, Governance), and corporate management, while also providing oversight to the health care business.

Mr. Lee began his LOTTE career as a researcher with Honam Petrochemical Corporation, now LOTTE Chemical Corporation, in 1990. Over the next three decades, he advanced through positions of increasing responsibility in R&D, Business Strategy & Planning, and New Business Planning & Development. He was named Chief Executive Officer of LOTTE Chemical Titan in 2010. In 2019, he was appointed as Chief Executive Officer of LOTTE Rental.

Under his leadership, LOTTE became an industry leader in the petrochemical and rental car businesses. He successfully led Post Merger Integration for the acquisition of Titan Chemical in Malaysia in 2010. LOTTE-Titan showed continuous growth and became one of the major companies in LOTTE Chemical. During Mr. Lee’s time as CEO of LOTTE Rental, the company’s revenue and asset value increased, resulting in LOTTE Rental ranked the #1 rental car brand in Korea.  This was enabled by Mr. Lee’s continual promotion of an inclusive and diverse culture.

Mr. Lee holds a bachelor’s degree in Chemical Engineering from Seoul National University.
Jong Soo Ha
Jong Soo Ha is the Vice President and Chief Financial Officer for LOTTE BIOLOGICS and serves on its Board of Directors.

Mr. Ha began his career at LOTTE in 2000 as a management team member with a focus on accounting and corporate strategy. In 2008, he was named the head of LOTTE Logistics' management strategy team. Since then, he has played a pivotal role in establishing LOTTE Logistics as a leader in the logistics industry. During his tenure as the head of the Strategic Management team, LOTTE Logistics showed continuous growth in the 3PL market, and expanded its global business by establishing overseas bases.

Mr. Ha also played a crucial role in the merger of LOTTE Logistics and LOTTE Global Logistics in 2019. His management and stewardship was essential to the smooth integration of the two companies.

Mr. Ha earned his BA in business administration from the University of Dong-A, Korea, and received a master of Business administration from Sogang University.
Makoto Miyashita
H. Joon Paek serves on the Board of Directors of LOTTE Biologics.

Dr. Paek has been working in the biologics industry for over 20 years, starting as a scientist at Tissue Genesis. Dr. Paek currently holds the position of Chief Operating Officer of Abrax Japan and Principal of Axil Capital Advisors K.K. During his extensive experience in the industry, he has published a number of patents in the fields of stem cell and tissue engineering.

Dr. Paek holds a master's degree in Polymer Chemistry from Kyoto University in Japan, a PhD in Biochemical Science from Brown University in Rhode Island, and a master of Business Administration from Waseda University in Japan.
Richard Schicho, PH.D.
Richard Schicho is a Corporate Advisor to LOTTE BIOLOGICS. As Corporate Advisor to LOTTE BIOLOGICS, Dr. Schicho provides guidance and advice to the team on technical matters related to biopharmaceutical manufacturing. Dr. Schicho joined LOTTE BIOLOGICS as an advisor in 4Q2021.

Dr. Schicho has enjoyed working with many talented teams throughout his career in biopharmaceutical development and manufacturing. Dr. Schicho has been driven by the opportunity to improve patients’ lives through the delivery of innovative biological medicines. Over the course of more than 25 years with several biopharmaceutical companies, he has been a key team member and leader in successful launches of new biopharmaceuticals and technology transfers of multiple products to sites around the world. Before joining LOTTE BIOLOGICS as Corporate Advisor, Dr. Schicho served as Director of Manufacturing Sciences and Technology at Takeda Pharmaceuticals. Prior to his work at Takeda, Dr. Schicho spent 13 years with Bristol Myers Squibb and 7 years with Schering-Plough.

A strong believer in the power of technology to improve the manufacturing process and the product quality of biopharmaceuticals, Dr. Schicho has led efforts to automate processes and leverage electronic systems for data analysis and modeling at multiple facilities.

Dr. Schicho earned a B.S. degree in Chemistry from Duke University in Durham, North Carolina and a Ph.D. degree in Chemical Engineering from The Johns Hopkins University in Baltimore, Maryland. He lives in Oxford, Georgia with his wife and has three grown children.

Our Leadership Team - USA

Dr. Hausladen
Dr. Hausladen is the General Manager of LOTTE BIOLOGICS USA. He has more than 25 years of experience in commercial and clinical manufacturing of Cell Therapies, Biologics, Pharmaceuticals, and Fine Chemicals.

Dr. Hausalden has held positions of increasing responsibility at Bristol-Myers Squibb (BMS). He began his career at BMS as an Engineer managing process improvements, facility startup, tech transfer and validation of the Cruiserath and Barceloneta sites for Irbesartan. As Associate Director of a Biologics Pilot Plant and Manufacturing Support, Dr. Hausladen successfully implemented multiple technical transfers under aggressive timelines and also provided technical direction and leadership for key manufacturing investigations.

Leveraging these diverse experiences, Dr. Hausladen successfully managed a Manufacturing department at BMS, providing strategic direction across Manufacturing Support, Clinical & R&D External Manufacturing, Validation, and Automation which led to the seamless implementation of new technologies and equipment. Before his appointment at LOTTE Biologics, he was Sr. Director of a Cell Therapy Facility in Devens, MA, leading a successful facility expansion and contributing to the supply of BMS CAR-T product Breyanzi.

Dr. Hausladen graduated from the State University of New York at Buffalo with bachelor’s, master’s, and doctoral degrees in Chemical Engineering.